Login Register Cart 0
Generic placeholder image

Current Women`s Health Reviews

Editor-in-Chief

ISSN (Print): 1573-4048
ISSN (Online): 1875-6581

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Association of Use of the Oral Contraceptive Pill (OCP) with the Expression Pattern of Different Molecular Subtypes of Breast Cancer

Author(s): Vitthal Khode, Sumangala Patil, Praveenkumar Shetty*, Udupi Shashtri Dinesh, Komal Ruikar, Anil Bargale and Satish G. Patil

Volume 18, Issue 2, 2022

Published on: 23 February, 2021

Article ID: e301021191755 Pages: 8

DOI: 10.2174/1573404817666210223165259

Price: $65

Abstract

Background: Triple-negative breast carcinoma (TNBC) is a breast cancer subtype associated with high mortality and inadequate therapeutic options when compared to non-TNBC. Clinical data indirectly suggests where Oral Contraceptive Pill (OCP) usage is high, the prevalence of Estrogen Receptor+ (ER+) breast cancer is high, and the prevalence of TNBC is low. This has lead to our hypothesis that OCP use may increase the risk of ER+ breast cancer, and OCP use may reduce the risk of TNBC. We aimed to compare the prevalence and association of subtypes of breast cancer in OCP users with that of non-users among women 30 to 60 years of age.

Methods: This hospital-based observational study of three-year duration included 155 subjects of primary invasive breast cancer who got admitted to our institution. The data was obtained for ER, PR, HER2 status, clinical classification, and data in relation to demographic factors, reproductive history, and history of OCP use. 155 subjects were divided into two groups. Group-1 included 48 patients with a history of OCP use, and group-2 included 107 patients who have not used OCP. Data was analysed using SPSS-20.

Results: A significant increase in the prevalence of molecular subtypes ER+, Progesterone Receptor+ (PR+) and Luminal B breast cancer in OCP users was observed compared to non-users. There was a significant decrease in the age at the time of admission in ER+ cancer in OCP users (45.3 years) compared to non-users (52.2 years). While age at the time of admission of Basal (TNBC) cancer patients in OCP users (53.1 years) was higher when compared to non-users (45.4 years). Upon logistic regression, the likelihood of ER+, PR+ and Luminal B in OCP users was 11%,10% and 13% less, respectively, with 1 year of higher age and the likelihood of TNBC in OCP users was 18% more and 8% less in non-users.

Conclusion: OCP use may be associated with increased prevalence of ER+, PR+ and Luminal B breast cancer. On the contrary, OCP use may be associated with a delay in the progression of the TNBC.

Keywords: Breast cancer, molecular subtype, oral contraceptive pill, estrogen, receptor+, triple-negative breast carcinoma, progesterone receptor.

Graphical Abstract

[1]
Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003; 100(14): 8418-23.
[2]
Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A. 100(18): 10393-8.
[http://dx.doi.org/10.1073/pnas.1732912100]
[3]
Trivers KF, Lund MJ, Porter PL, et al. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control 2009; 20(7): 1071-82.
[http://dx.doi.org/10.1007/s10552-009-9331-1] [PMID: 19343511]
[4]
Gaudet MM, Press MF, Haile RW, et al. Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger. Breast Cancer Res Treat 2011; 130(2): 587-97.
[http://dx.doi.org/10.1007/s10549-011-1616-x] [PMID: 21667121]
[5]
Yang XR, Sherman ME, Rimm DL, et al. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 2007; 16(3): 439-43.
[http://dx.doi.org/10.1158/1055-9965.EPI-06-0806] [PMID: 17372238]
[6]
Ma H, Wang Y, Sullivan-Halley J, et al. Use of four biomarkers to evaluate the risk of breast cancer subtypes in the women’s contraceptive and reproductive experiences study. Cancer Res 2010; 70(2): 575-87.
[http://dx.doi.org/10.1158/0008-5472.CAN-09-3460] [PMID: 20068186]
[7]
Yang XR, Chang-Claude J, Goode EL, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst 2011; 103(3): 250-63.
[http://dx.doi.org/10.1093/jnci/djq526] [PMID: 21191117]
[8]
Palmer JR, Boggs DA, Wise LA, Ambrosone CB, Adams-Campbell LL, Rosenberg L. Parity and lactation in relation to estrogen receptor negative breast cancer in African American women. Cancer Epidemiol Biomarkers Prev 2011; 20(9): 1883-91.
[http://dx.doi.org/10.1158/1055-9965.EPI-11-0465] [PMID: 21846820]
[9]
Li Li, Zhong Y, Zhang H, et al. Association between oral contraceptive use as a risk factorand triple-negative breast cancer: A systematic review and meta-analysis. Molecular and clinical oncology 2017; 7: 76-80.
[10]
Warner ET, Tamimi RM, Boggs DA, et al. Estrogen receptor positive tumors: do reproductive factors explain differences in incidence between black and white women? Cancer Causes Control 2013; 24(4): 731-9.
[http://dx.doi.org/10.1007/s10552-013-0153-9] [PMID: 23380944]
[11]
Rosato V, Bosetti C, Negri E, et al. Reproductive and hormonal factors, family history, and breast cancer according to the hormonal receptor status. Eur J Cancer Prev 2013.
[PMID: 23817433]
[12]
Phipps AI, Buist DS, Malone KE, et al. Reproductive history and risk of three breast cancer subtypes defined by three biomarkers. Cancer Causes Control 2011; 22(3): 399-405.
[http://dx.doi.org/10.1007/s10552-010-9709-0] [PMID: 21184265]
[13]
Yan Y, Li X, Blanchard A, et al. Expression of both estrogen receptor-beta 1 (ER-β1) and its co-regulator steroid receptor RNA activator protein (SRAP) are predictive for benefit from tamoxifen therapy in patients with estrogen receptor-alpha (ER-α)-negative early breast cancer (EBC). Ann Oncol 2013; 24(8): 1986-93.
[http://dx.doi.org/10.1093/annonc/mdt132] [PMID: 23579816]
[14]
Hammond MEH, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 2010; 134(7): e48-72.
[PMID: 20586616]
[15]
Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11(2): 155-68.
[PMID: 9504686]
[16]
Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347(9017): 1713-27.
[http://dx.doi.org/10.1016/S0140-6736(96)90806-5] [PMID: 8656904]
[17]
Sung H, Rosenberg PS, Chen WQ, et al. Female breast cancer incidence among Asian and Western populations: more similar than expected. J Natl Cancer Inst 2015; 107(7): 107.
[http://dx.doi.org/10.1093/jnci/djv107] [PMID: 25868578]
[18]
Youlden DR, Cramb SM, Yip CH, Baade PD. Incidence and mortality of female breast cancer in the Asia-Pacific region. Cancer Biol Med 2014; 11(2): 101-15. PMID: 25009752
[19]
Pandit P, Patil R, Palwe V, Gandhe S, Patil R, Nagarkar R. Prevalence of molecular subtypes of breast cancer: A single institutional experience of 2062 patients. Eur J Breast Health 2020; 16(1): 39-43.
[20]
Mane A, Khatib KI, Deshmukh SP, Nag SM, Sane SP, Zade BP. A comparison of clinical features, pathology and outcomes in various subtypes of breast cancer in Indian women. J Clin Diagn Res 2015; 9(9): PC01-4.
[http://dx.doi.org/10.7860/JCDR/2015/15253.6461] [PMID: 26500944]
[21]
Shin HR, Joubert C, Boniol M, et al. Recent trends and patterns in breast cancer incidence among Eastern and Southeastern Asian women. Cancer Causes Control 2010; 21(11): 1777-85.
[http://dx.doi.org/10.1007/s10552-010-9604-8] [PMID: 20559704]
[22]
Bray F, McCarron P, Parkin DM. The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res 2004; 6(6): 229-39.
[http://dx.doi.org/10.1186/bcr932] [PMID: 15535852]
[23]
Liu L, Zhang J, Wu AH, Pike MC, Deapen D. Invasive breast cancer incidence trends by detailed race/ethnicity and age. Int J Cancer 2012; 130(2): 395-404.
[http://dx.doi.org/10.1002/ijc.26004] [PMID: 21351091]
[24]
Leong SP, Shen ZZ, Liu TJ, et al. Is breast cancer the same disease in Asian and Western countries? World J Surg 2010; 34(10): 2308-24.
[http://dx.doi.org/10.1007/s00268-010-0683-1] [PMID: 20607258]
[25]
Martin AM, Weber BL. Genetic and hormonal risk factors in breast cancer. J Natl Cancer Inst 2000; 92(14): 1126-35.
[http://dx.doi.org/10.1093/jnci/92.14.1126] [PMID: 10904085]
[26]
Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000; 343(2): 78-85.
[http://dx.doi.org/10.1056/NEJM200007133430201] [PMID: 10891514]
[27]
Thompson D, Easton D. The genetic epidemiology of breast cancer genes. J Mammary Gland Biol Neoplasia 2004; 9(3): 221-36.
[http://dx.doi.org/10.1023/B:JOMG.0000048770.90334.3b] [PMID: 15557796]
[28]
Hinsche O, Girgert R, Emons G, Gründker C. Estrogen receptor β selective agonists reduce invasiveness of triple-negative breast cancer cells. Int J Oncol 2015; 46(2): 878-84.
[http://dx.doi.org/10.3892/ijo.2014.2778] [PMID: 25420519]
[29]
Girgert R, Emons G, Gründker C. Inhibition of growth hormone receptor by Somavert reduces expression of GPER and prevents growth stimulation of triple-negative breast cancer by 17β-estradiol. Oncol Lett 2018; 15(6): 9559-66.
[http://dx.doi.org/10.3892/ol.2018.8521] [PMID: 29805678]

Rights & Permissions Print Cite
Article Metrics
11
1
© 2024 Bentham Science Publishers | Privacy Policy